Abstract: The invention relates to novel hybrid cholinesterase inhibitors containing the melatonin or its oxidation products unit and tetrahydroacridine unit linked via a carbamate bond. Due to the high selectivity of action, which is expressed with high ratio of IC50 for acetylcholinesterase inhibition to IC50 for butyrylcholinesterase inhibition ([IC50(AChE)]/[IC50(BChE)]), the novel compounds may be used in relief and/or treatment of the neurodegenerative diseases, among them the Alzheimer's disease.
Type:
Grant
Filed:
November 22, 2013
Date of Patent:
September 23, 2014
Assignees:
Uniwersytet Warszawski, Centrum Medyczne Ksztalcenia Podyplomowego
Inventors:
Anna Zawadzka, Zbigniew Czarnocki, Iwona Lozinska, Zuzanna Moleda, Miroslawa Panasiewicz
Abstract: The invention relates to novel hybrid cholinesterase inhibitors containing the melatonin or its oxidation products unit and tetrahydroacridine unit linked via a carbamate bond. Due to the high selectivity of action, which is expressed with high ratio of IC50 for acetylcholinesterase inhibition to IC50 for butyrylcholinesterase inhibition ([IC50(AChE)]/[IC50(BChE)]), the novel compounds may be used in relief and/or treatment of the neurodegenerative diseases, among them the Alzheimer's disease.
Type:
Application
Filed:
November 22, 2013
Publication date:
March 20, 2014
Applicants:
CENTRUM MEDYCZNE KSZTALCENIA PODYPLOMOWEGO, UNIWERSYTET WARSZAWSKI
Inventors:
Anna Zawadzka, Zbigniew Czarnocki, Iwona Lozinska, Zuzanna Moleda, Miroslawa Panasiewicz